This will enable the immediate commercialisation of DARC as an exploratory bio-marker for use in clinical trials in the field of glaucoma and AMD.

The funding will also allow the continued development of DARC as a diagnostic, following a successful Phase III study. 

If you are interested in receiving further information regarding the Series A investment process and status please register your details below:


 

 
 

WANT TO GET INVOLVED?

Get in touch for more information
or email:

contact@illustratum.net